News

Discover what is going on in the network of the LIFE Cooperative. Find here updates about members, the ecosystem en important announcements.

24 articles
We 17 January 2024

Sabiad secures investment from Pharma Connect Capital for Staphylococcus Aureus research

Sabiad, een start-up in Heerenveen, lid van de LIFE Cooperative en onderdeel van het Open Diagnostics Ecosystem, ontving onlangs een aanzienlijke investeringssteun van Pharma Connect Capital (PCC). Deze financiering zal de lancering van hun grensverleggende initiatief ondersteunen. Het project, in samenwerking met het Universitair Medisch Centrum Groningen (UMCG), is gericht op het ontwikkelen van een antilichaam dat de detectie en beeldvorming van Staphylococcus aureus-infecties - een aanzienlijke uitdaging, vooral na orthopedische implantaties zoals heup- en knieprotheses mogelijk maakt.

Tu 19 December 2023

Groundbreaking Results Cement North Netherlands' Role in Diagnostic Innovation within the Open Diagnostics Ecosystem

The goal behind the establishment of the Open Diagnostics Ecosystem (ODE) was crystal clear in the spring of 2020: to bolster and market the position of North Netherlands as a global player in the field of (medical) diagnostics. As the project draws to a close in December 2023, the initiators reflect upon an exceedingly successful journey. Ton Vries, Chairman of the LIFE Cooperative and initiator of ODE, states, "In a relatively short period, we've successfully shepherded nine projects from eight different companies within ODE. The results of these companies speak volumes: the network infrastructure and substantive financial support have led to tremendous achievements in diagnostics. We take exceptional pride in this."

We 27 September 2023

Necessity of medicine production in the Netherlands undisputed during the second LIFE Sciences Conference

Medicine shortages are still increasing in the Netherlands. Doctors and pharmacists have been sounding the alarm for some time now because crucial medicines are increasingly unavailable to patients. The need for medicine production in the Netherlands is indisputable, but how do you start and strengthen this process? This issue was central during the second edition of the LIFE Sciences Conference on Tuesday, September 26, 2023, led by chairperson Rosanne Hertzberger, in a sold-out Forum Groningen. During this conference, the LIFE Cooperative, together with partners, once again brought together the players of the Life Science & Health sector in (Northern) Netherlands, this year under the theme 'Bringing Back Drug Manufacturing to the Netherlands'.

Mo 25 September 2023

EFRO-subsidie toegekend door SNN aan ParaMedir

ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland). This subsidy will support a groundbreaking consortium led by ParaMedir in their mission to improve healthcare through innovative (bio)monitoring solutions. Next to the subsidy granted by the SNN, the province of Groningen and the municipality of Groningen have both agreed to finance this project as well, contributing about €130,000.00, underlining the importance of this project for the region.

We 5 July 2023

Reyedar (prev. Reperio Medtech) Secures €3 Million Investment to Revolutionize Degenerative Disease Screening by combining Eye Tracking and Deep Learning

Reyedar, een deeptech startup en LIFE Cooperative lid die vroegtijdige screening van leeftijdsgerelateerde degeneratieve ziekten mogelijk maakt, kondigt vandaag aan dat het een investering van € 3 miljoen heeft binnengehaald om zijn baanbrekende oplossing verder te ontwikkelen. Reyedar ontwikkelt een eigen medisch technologieplatform op basis van eye tracking en deep learning waarmee veel symptomen van leeftijdsgerelateerde ziekten vroegtijdig kunnen worden gedetecteerd. De financieringsronde wordt geleid door Cottonwood Technology Fund, een toonaangevend durfkapitaal fonds dat investeert in technologiebedrijven in een vroeg stadium. NOM, Pupil Labs, Uneti Ventures en de reeds bestaande investeerder Blue Sparrows MedTech Fund doen ook mee in deze investeringsronde.

We 13 July 2022

Official Allocation of €78.8 Million for PharmaNL from the National Growth Fund!

Today, the National Growth Fund announced that PharmaNL has met the conditions to convert the conditional allocation of €78.8 million into a definitive grant. “We at PharmaNL are delighted with this news. Together with stakeholders, we can now begin implementing the ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.